Sallam Tamer, Jones Marius C, Gilliland Thomas, Zhang Li, Wu Xiaohui, Eskin Ascia, Sandhu Jaspreet, Casero David, Vallim Thomas Q de Aguiar, Hong Cynthia, Katz Melanie, Lee Richard, Whitelegge Julian, Tontonoz Peter
Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, California 90095, USA.
Department of Medicine, Division of Cardiology, University of California, Los Angeles, California 90095, USA.
Nature. 2016 Jun 2;534(7605):124-8. doi: 10.1038/nature17674. Epub 2016 May 11.
Liver X receptors (LXRs) are transcriptional regulators of cellular and systemic cholesterol homeostasis. Under conditions of excess cholesterol, LXR activation induces the expression of several genes involved in cholesterol efflux, facilitates cholesterol esterification by promoting fatty acid synthesis, and inhibits cholesterol uptake by the low-density lipoprotein receptor. The fact that sterol content is maintained in a narrow range in most cell types and in the organism as a whole suggests that extensive crosstalk between regulatory pathways must exist. However, the molecular mechanisms that integrate LXRs with other lipid metabolic pathways are incompletely understood. Here we show that ligand activation of LXRs in mouse liver not only promotes cholesterol efflux, but also simultaneously inhibits cholesterol biosynthesis. We further identify the long non-coding RNA LeXis as a mediator of this effect. Hepatic LeXis expression is robustly induced in response to a Western diet (high in fat and cholesterol) or to pharmacological LXR activation. Raising or lowering LeXis levels in the liver affects the expression of genes involved in cholesterol biosynthesis and alters the cholesterol levels in the liver and plasma. LeXis interacts with and affects the DNA interactions of RALY, a heterogeneous ribonucleoprotein that acts as a transcriptional cofactor for cholesterol biosynthetic genes in the mouse liver. These findings outline a regulatory role for a non-coding RNA in lipid metabolism and advance our understanding of the mechanisms that coordinate sterol homeostasis.
肝脏X受体(LXRs)是细胞和全身胆固醇稳态的转录调节因子。在胆固醇过量的情况下,LXR激活会诱导几种参与胆固醇流出的基因表达,通过促进脂肪酸合成来促进胆固醇酯化,并抑制低密度脂蛋白受体对胆固醇的摄取。大多数细胞类型以及整个生物体中甾醇含量都维持在狭窄范围内,这一事实表明调节途径之间必定存在广泛的相互作用。然而,将LXRs与其他脂质代谢途径整合的分子机制尚未完全了解。在此我们表明,小鼠肝脏中LXRs的配体激活不仅促进胆固醇流出,还同时抑制胆固醇生物合成。我们进一步确定长链非编码RNA LeXis是这种效应的介导因子。西式饮食(高脂肪和高胆固醇)或药理学上的LXR激活可强烈诱导肝脏中LeXis的表达。提高或降低肝脏中LeXis的水平会影响参与胆固醇生物合成的基因表达,并改变肝脏和血浆中的胆固醇水平。LeXis与RALY相互作用并影响其与DNA的相互作用,RALY是一种异质性核糖核蛋白,在小鼠肝脏中作为胆固醇生物合成基因的转录辅因子。这些发现概述了一种非编码RNA在脂质代谢中的调节作用,并加深了我们对协调甾醇稳态机制的理解。